• 1
    Correll C, Manu P, Olshanskiy V, Napolitano B, Kane J, Malhotra A. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 17651773.
  • 2
    Barnett AH, Mackin P, Chaudhry I et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. (Perspective). J Psychopharmacol 2007 July; 21: 357373.
  • 3
    Marder SR, Essock SM, Miller AL et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004 Aug; 161: 13341349.
  • 4
    Baptista T, De Mendoza S, Beaulieu S, Bermudez A, Martinez M. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. Metab Syndr Relat Disord 2004; 2: 290307.
  • 5
    Holt R, Peveler R. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab 2009; 11: 665679.
  • 6
    Koro CE, Fedder DO, L’Italien GL et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J 2002; 325: 243249.
  • 7
    Reaven GM, Lieberman JA, Sethuraman G et al. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. J Psychiatr Res 2009 Jul; 43: 9971002.
  • 8
    Beebe KL, Block T, Debattista C et al. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Behav Brain Res 2006; 171: 225229.
  • 9
    Gross C, Blasey C, Roe R et al. Mifepristone treatment of olanzapine induced weight gain in healthy men. Adv Ther 2009; 26(10): 959969.
  • 10
    Belanoff J. Mifepristone reduces weight gain associated with risperidone use. Poster presented at 40th Annual ISPNE; July 2009; San Francisco, California.
  • 11
    Clark RD, Ray NC, Williams K et al. 1H-Pyrazolo [3,4-g] hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity. Bioorg Med Chem Lett 2008 Feb 15; 18: 13121317.
  • 12
    Asagami T, Clark R, Belanoff J, Tsao P. A new selective glucocorticoid antagonist suppresses body weight gain as well as improves insulin sensitivity. Abstract presented at the Annual Meeting of the American Diabetes Association; 2009; New Orleans, LA.